BIOMAT Database Logo BIOMAT Database Logo

Paradoxical worsening of parkinsonism upon neuroleptic withdrawal: More common than we think? 2018

Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Movement Disorders Section, Department of Neurological Sciences, University of Nebraska Medical Center, United States.

UI MeSH Term Description Entries
D008297 Male Males
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077152 Olanzapine A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy. 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine,LY 170053,LY-170052,Olanzapine Pamoate,Zolafren,Zyprexa,LY 170052,LY170052
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001714 Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. Affective Psychosis, Bipolar,Bipolar Disorder Type 1,Bipolar Disorder Type 2,Bipolar Mood Disorder,Depression, Bipolar,Manic Depression,Manic Disorder,Manic-Depressive Psychosis,Psychosis, Manic-Depressive,Type 1 Bipolar Disorder,Type 2 Bipolar Disorder,Psychoses, Manic-Depressive,Bipolar Affective Psychosis,Bipolar Depression,Bipolar Disorders,Bipolar Mood Disorders,Depression, Manic,Depressions, Manic,Disorder, Bipolar,Disorder, Bipolar Mood,Disorder, Manic,Manic Depressive Psychosis,Manic Disorders,Mood Disorder, Bipolar,Psychoses, Bipolar Affective,Psychoses, Manic Depressive,Psychosis, Bipolar Affective,Psychosis, Manic Depressive
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D018020 Lithium Compounds Inorganic compounds that contain lithium as an integral part of the molecule. Compounds, Lithium

Related Publications

Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Hemochromatosis: more common than we think.
July 1977, Medical times,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
UTIs. More common than we think?
April 2001, Nursing management,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Female masturbation--more common than we think.
March 1971, Medical times,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Gouty tenosynovitis--more common than we think?
January 2004, The New Zealand medical journal,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Bickerstaff brainstem encephalitis: more common than we think?
November 2013, Journal of neurology, neurosurgery, and psychiatry,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Strongyloidiasis: a diagnosis more common than we think.
July 2012, European journal of gastroenterology & hepatology,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Angiotropic malignant melanoma: more common than we think?
May 2001, Journal of the American Academy of Dermatology,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Low-renin hypertension: more common than we think?
January 2000, Cardiology in review,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Hallucinations in nonpsychotic children: more common than we think?
May 1999, Journal of the American Academy of Child and Adolescent Psychiatry,
Ada Florescu, and David Whitney, and Danish Bhatti, and John M Bertoni, and Diego Torres-Russotto
Cannabinoid hyperemesis--is it more common than we think?
January 2013, The Journal of the Arkansas Medical Society,
Copied contents to your clipboard!